Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
All >

Deals > Switzerland

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Switzerland or involving Swiss organisations.

Total search results: 1149 | Ordered by Deal: Collaboration or Financing (descending)
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Zogenix–HBM: investment, 202201 investment existent at time of $1.76b cash tender offer for Zogenix by UBS 2022-01-19
Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab 2022-06-16
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG 2020-09-28
XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG 2018-10-24
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares 2016-12-19
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners 2017-01-05
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies 2018-02-26
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution 2017-06-01
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest 2019-04-30
Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund 2017-05-04
Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund 2017-05-04
Visus Therapeutics–Wille Finance: investment, 202103 financing round Series A totalling $36m incl investor Wille AG 2021-03-09
Vifor Pharma–Evotec: drug RnD, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w 2019-11-06
Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED 2021-12-14
Vertex–CRISPR Therapeutics: CRISPR technology, 202303– license non-excl $100m upfront + $230m milestones + royalties CRISPR/Cas9 for cell therapies 2023-03-27
Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products 2019-06-06
Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB 2019-09-18
Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners 2017-03-29
Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners 2019-09-17
Versantis–Genfit: investment, 202209– acquisition CHF40m upfront + CHF65m milestones + 1/3 of net proceeds of eventual PRV 2022-09-19
Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m 2019-10-17
Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m 2018-12-18
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Vector BioPharma–Versant Ventures: investment, 202208 company emerges with $30m Series A commitment from Versant Ventures 2022-08-10
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group 2020-01-07
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures 2020-01-07
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors 2020-01-07
VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market 2021-04-08
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m 2022-03-30
VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share 2023-05-21
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative 2020-01-07
VectivBio–Forbion: investment, 202305 existent shareholder Forbion 2023-05-01
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors 2020-01-07
Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem 2019-11-12
Vandria–SEVERAL: investment, 202312 emerges from stealth with financing round Series A CHF18m led by +ND Capital 2023-12-14
Vandria–OTHER: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl small syndicate of HNW private investors 2023-12-14
Vandria–+ND Capital: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl lead investor +ND Capital 2023-12-14
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments 2021-01-11
Valerius Biopharma–Catalent: contract manufacturing, 201805– collab cell line developm + manufacturing of speciality biosimilars using GPEx technology 2018-05-14
Vaderis Therapeutics–Medicxi: investment, 2020 Series A financing CHF18m from Medicxi 2020-01-01
Vaderis Therapeutics–Almac: allosteric AKT inhibitors, 202004 acquisition portfolio of allosteric AKT inhibitors from Almac Discovery Ltd by Vedaris 2020-04-01
Upstream Bio–HBM: investment, 202206 financing round Series A totalling $200m incl co-investor HBM Healthcare Investments 2022-06-02
Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer 2019-08-26
UbiSim–Labster: investment, 202110– acquisition of UbiSim by Labster SIGNED 2021-10-14
Twist Bioscience–Genedata: bioinformatics, 202002 supply existent Twist is existing customer of Genedata 2020-02-26
Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF 2018-09-06
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics 2018-09-28
Turnstone Biologics–Scailyte: biomarker discovery, 202303– collab biomarker discovery for TIL therapy using ScaiVision platform 2023-03-16
Tubulis–Occident: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Occident 2024-03-14
Tubulis–Occident: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident 2022-05-03
Tubulis–Occident: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group 2020-07-21
Tubulis–Nextech: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor Nextech Invest Ltd 2024-03-14
Tubulis–BioMedPartners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor BioMedPartners 2024-03-14
Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners 2022-05-03
Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners 2020-07-21
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
Tricares–BioMedPartners: investment, 202209 financing round Series C 1st closing totalling €47m incl existing + co-investor BioMed Partners 2022-09-15
TraitGenetics–SGS: investment, 201802 acquisition of TraitGenetics GmbH by SGS 2018-02-02
Topas Therapeutics–BioMedPartners: investment, 202107 financing round Series B extension €18m incl existing investor BioMedPartners 2021-07-29
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor ZKB 2020-06-09
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB 2018-09-24
Tolremo Therapeutics–SEVERAL: investment, 202006 financing round Series A 2nd closing CHF4.7m bringing total Series A to CHF13.7m 2020-06-09
Tolremo Therapeutics–SEVERAL: investment, 201809 financing round Series A CHF9m led by BioMedPartners 2018-09-24
Tolremo Therapeutics–SEVERAL: investment, 201709 seed financing round CHF2.4m 2017-09-18
Tolremo Therapeutics–Redalpine: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor Redalpine VP 2020-06-09
Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine 2018-09-24
Tolremo Therapeutics–OTHER: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing private biotech investors 2020-06-09
Tolremo Therapeutics–BioMedPartners: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor BMP 2020-06-09
Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners 2018-09-24
Tolremo Therapeutics–Altos Venture: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor Altos 2020-06-09
Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture 2018-09-24
Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 2017-01-04
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana 2014-12-01
ThromboGenics–Sachs Associates: investor conference, 201709 supply service ThromboGenics presents at Sachs Biotech in Europe Forum in Basel 2017-09-26
ThromboGenics–Novartis: investment, 201709–201801 equity investment €10m by Novartis after termination of Jetrea agreement 2017-09-18
Thermo Fisher–Univ Basel: DNA sequencing, 201704– collab Univ Hospital joins NGS Companion Dx Center of Excellence Program 2017-04-18
Thermo Fisher–Biognosys: mass spectrometry s/w, 201706– collab co-marketing of Spectronaut Pulsar s/w with Orbitrap mass spectrometers 2017-06-05
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Pfizer: investment, 201905–201907 acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
TG Therapeutics–Novimmune: bispecific antibody, 201806– collab + excl license option ww for CD47/CD19 antibody NI-1701 (TG-1801) 2018-06-20
Terns Pharmaceuticals–Samsara Capital: investment, 202101 financing round Series C totalling $87m incl co-investor Samsara Capital 2021-01-05
Teneobio–Selexis: cell line development, 201706– supply service access to SUREtechnology platform to develop cell expression of UniAbs 2017-06-12
Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh 2023-05-02
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group 2020-07-16
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top